Hotchkis & Wiley Capital Management
VNDA icon

Hotchkis & Wiley Capital Management’s Vanda Pharmaceuticals VNDA Stock Holding History

Hotchkis & Wiley Capital Management’s Portfolio VNDA Stock Details VNDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-1,255,000
Closed -$8.27M – 534
2023
Q2 		$8.27M Buy
1,255,000
+223,140
+22% +$1.43M 0.03% 239
2023
Q1 		$7.01M Buy
1,031,860
+56,600
+6% +$398K 0.03% 278
2022
Q4 		$7.21M Buy
975,260
+36,070
+4% +$351K 0.03% 251
2022
Q3 		$9.28M Buy
939,190
+37,460
+4% +$396K 0.04% 138
2022
Q2 		$9.83M Sell
901,730
-10,730
-1% -$111K 0.04% 141
2022
Q1 		$10.3M Buy
912,460
+368,770
+68% +$4.85M 0.03% 166
2021
Q4 		$8.53M Buy
543,690
+284,270
+110% +$4.95M 0.03% 218
2021
Q3 		$4.45M Sell
259,420
-3,880
-1% -$68K 0.01% 356
2021
Q2 		$5.66M Buy
263,300
+20,500
+8% +$367K 0.02% 301
2021
Q1 		$3.65M Sell
242,800
-23,690
-9% -$383K 0.01% 385
2020
Q4 		$3.5M Buy
+266,490
New +$3.21M 0.01% 352

Other funds holding VNDA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Hotchkis & Wiley Capital Management's VNDA Position: Q3 2023 in Review

Hotchkis & Wiley Capital Management sold out of Vanda Pharmaceuticals (VNDA) in Q3 2023, closing a stake of 1,255,000 shares — an estimated $8.27M sold.

Hotchkis & Wiley Capital Management first reported a position in VNDA in Q4 2020 and held it in 11 quarters. The position peaked at $10.3M in Q1 2022. 179 funds tracked by Wall St. Rank hold VNDA as of Q3 2023.

  • Hotchkis & Wiley Capital Management reported no remaining Vanda Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
  • Hotchkis & Wiley Capital Management sold 1,255,000 Vanda Pharmaceuticals shares in Q3 2023, an estimated $8.27M.
  • Hotchkis & Wiley Capital Management first reported a position in Vanda Pharmaceuticals in Q4 2020 and held it in 11 quarters.
  • Hotchkis & Wiley Capital Management's Vanda Pharmaceuticals position peaked at $10.3M in Q1 2022.
  • 179 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q3 2023.

Based on Hotchkis & Wiley Capital Management's 13F filing for Q3 2023, filed 13 Nov 2023.